CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...
Phase 1, Phase 2
Portland, Oregon, United States and 26 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Portland, Oregon, United States and 66 other locations
T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma...
Phase 1
Portland, Oregon, United States and 3 other locations
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating re...
Phase 2
Portland, Oregon, United States
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Portland, Oregon, United States and 203 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Portland, Oregon, United States and 195 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Portland, Oregon, United States and 171 other locations
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...
Phase 3
Portland, Oregon, United States and 219 other locations
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancre...
Early Phase 1
Portland, Oregon, United States
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), tar...
Phase 1
Portland, Oregon, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal